ArticleJournal of human hypertension2011
Dyslipidaemia, combined oral contraceptives use and their interaction on the risk of hypertension in Chinese women.
Article in Journal of human hypertension, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2017Pooled it
- Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges.Current hypertension reports · 2026Review
- The use of oral contraceptives and the risks of developing prehypertension and hypertension in women of reproductive age: findings from a population-based survey in Indonesia.BMC public health · 2025Article
- Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations.Hypertension (Dallas, Tex. : 1979) · 2023Review
- The effects of the interaction between BMI and dyslipidemia on hypertension in adults.Scientific reports · 2022Article
- Oral contraceptives and hypertension in women: results of the enrolment phase of Tabari Cohort Study.BMC women's health · 2021Article
- Article
- Combined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expression.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
- Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women.BMC women's health · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study was to assess the associations of dyslipidaemia, combined oral contraceptive (COC) use and their interaction on the risk of hypertension in Chinese women. In a case-control study, we evaluated 665 hypertensive women and 665 normotensive women matched on region and age in China. Hypertensive women had a higher prevalence of dyslipidaemia and higher levels of total cholesterol, triglyceride, low-density lipoprotein-cholesterol and lipoprotein a than normotensive ones (P<0.05). The risk of hypertension gradually increased with the increasing cumulative time of COC use in women (P=0.0043), especially significantly increased among those with cumulative time of COC use 15-20 and ≥20 years (adjusted odds ratio (OR)=1.46, 95% confidence interval (CI): 1.00-2.15; OR=1.49, 95% CI: 1.06-2.11), but gradually decreased from stopping use of COC (P<0.0001). The multiplicative interaction between dyslipidaemia and accumulative time of COC use ≥15 years, dyslipidaemia and family history of hypertension, or family history of hypertension and accumulative time of COC use ≥15 years was confirmed and the interaction analyses showed that they can significantly increased the risk of hypertension (adjusted OR=2.82, 95% CI: 1.59-3.27; OR=4.33, 95% CI: 3.10-6.06; OR=4.56, 95% CI: 3.07-6.77). It is concluded that dyslipidaemia, accumulative time of COC use ≥15 years and their interaction increased the risk of hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.